arGentis Pharmaceuticals, LLC is a privately-held diversified biopharmaceutical company dedicated to the licensing, development and commercialization of novel classes of therapies to treat chronic diseases in autoimmunity and ophthalmology. arGentis’ drug R&D programs are focused on treating underlying mechanisms of unmet inflammatory conditions through utilization of oral and transdermal compounds. Visit their website

"ArGentis, Innova's first portfolio company, has benefited from their support and guidance on key development and capital strategies. Their belief in our science and their support of our management team has assisted us as we develop our clinical and commercialization approaches and move forward to bring our treatments to market."
- Tom I. Davis, II CEO